Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL107027 | 0.82 | EGLN2 (0.36) | — | |
| SCHEMBL3491364 | 0.79 | PTPN1 (0.36) | HSD11B1PTPN1 | |
| SCHEMBL3490389 | 0.79 | HSD11B1 (0.32) | HSD11B1HSD11B2 | |
| SCHEMBL3513520 | 0.75 | HSD11B1 (0.57) | HSD11B1HSD11B2PTPN1 | |
| SCHEMBL17027695 | 0.75 | HSD11B1 (0.57) | HSD11B1HSD11B2PTPN1 | |
| SCHEMBL30797244 | 0.73 | — | — | |
| SCHEMBL19260907 | 0.71 | EGLN2 (0.38) | — | |
| SCHEMBL3491362 | 0.70 | PTPN1 (0.35) | HSD11B1PTPN1 | |
| SCHEMBL123714 | 0.69 | PTPN1 (0.33) | PTPN1 | |
| SCHEMBL16335328 | 0.69 | PTPN1 (0.42) | HSD11B1HSD11B2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155769-B1 | TISSUE DEGENERATION PROTECTION | UNIV LEUVEN KATH (BE) | 2012-06-27 | — | — | EP | disclosed |
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | GEUNS JOANNES | 2010-04-22 | — | — | US | disclosed |
| EP-2155769-A2 | TISSUE DEGENERATION PROTECTION | Katholieke Universiteit Leuven (BE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008134828-A2 | TISSUE DEGENERATION PROTECTION | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | SORD, CASP3, TXNRD2 | HSD11B1 187/4885MEN1 3683/4885KMT2A 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.